Sanofi Reports Strong First Quarter 2026 Results
Sanofi announced double-digit sales and business EPS growth for the first quarter of 2026, driven by strong performance from new pharmaceutical launches and existing key products.
Paris – Sanofi reported its first-quarter 2026 financial results on April 23, 2026, showcasing significant growth. The company's total sales increased by 13.6% at constant exchange rates (CER), reaching €10,509 million. Business earnings per share (EPS) grew by 14.0% CER.
The performance was notably bolstered by the company's pharmaceutical launches, which saw sales surge by 49.6% to €1.2 billion. Key drivers included Dupixent, ALTUVIIIO, and Sarclisa. Dupixent itself continued its strong trajectory, with sales increasing by 30.8% to €4.2 billion, marking a robust start to the year. Vaccines also contributed positively, with sales rising 2.1% to €1.3 billion, aided by the Heplisav-B vaccine.
Sanofi also highlighted advancements in its pipeline. The company secured five regulatory approvals, all within the immunology sector. Additionally, positive Phase 3 trial results were reported for venglustat for a rare disease, and encouraging Phase 2 data emerged for lunsekimig in respiratory diseases. The acquisition of Dynavax was completed as part of its strategic capital allocation.
Research and development expenses reached €1.7 billion, a modest 1.5% increase. Selling and general expenses saw a more significant rise of 11.6% to €2.3 billion, largely due to recent acquisitions. Sanofi reiterated its full-year 2026 outlook, expecting high single-digit sales growth and slightly faster business EPS growth at CER, indicating continued profitable expansion.